Wirksamkeit und Sicherheit von magensaftresistentem Phosphatidylcholin-Granulat (LT-02) in der Remissionsinduktion bei Colitis ulcerosa Patienten mit ungenügendem Ansprechen auf Mesalazin: eine randomisierte, doppelblinde, Plazebo-kontrollierte Studie
Axel Dignaß(Goethe University Frankfurt), Wolfgang Stremmel(University Hospital Heidelberg), Klaus Fellermann(Apple (Israel)), M Horyński, W Reinisch, Jost Langhorst(ThyssenKrupp (Germany)), Gottfried Novacek(Medical University of Vienna), P Übel, H Heinemann(Dr Falk Pharma (Germany)), Peter Hasselblatt(University Medical Center Freiburg), Roland Greinwald(Dr Falk Pharma (Germany)), P Armerding, О. І. Poyda(Bogomolets National Medical University), J Stein, Rudolf Müller(University of Hohenheim), Tanja Kühbacher(University Hospital Schleswig-Holstein)
Cited by 0
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k
Survival and Causes of Death in Cirrhotic and in Noncirrhotic Patients with Primary Hemochromatosis
|New England Journal of Medicine|1985|1.1k
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969